脂蛋白(a):归来者
综述指出,孟德尔随机化研究为高脂蛋白(a)浓度与心血管疾病及主动脉瓣狭窄的因果作用提供了有力支持。目前三种降低脂蛋白(a)的治疗途径包括脂蛋白血浆置换、PCSK9抑制剂(降低约30%)和靶向载脂蛋白(a)的反义疗法(1/2期试验中最高降低90%)。反义疗法的3期结局研究结果尚未公布。
要点
- 孟德尔随机化研究支持高脂蛋白(a)浓度与心血管疾病及主动脉瓣狭窄存在因果关联。
- PCSK9抑制剂在降低低密度脂蛋白胆固醇的同时可降低脂蛋白(a)约30%。
- 靶向载脂蛋白(a)的反义疗法在1/2期试验中特异性降低脂蛋白(a)最高达90%,不影响其他血脂。
核心结论
- 高脂蛋白(a)浓度可能对心血管疾病具有保护性,降低高脂蛋白(a)浓度可能具有保护作用,但需等待反义疗法3期结局研究结果。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 孟德尔随机化方法首次为高脂蛋白(a)浓度在心血管疾病中的因果作用提供了有力支持,后又支持其与主动脉瓣狭窄的因果作用。
- 脂蛋白血浆置换(特异性或非特异性针对脂蛋白(a))可显著降低脂蛋白(a)浓度及心血管终点事件。
- PCSK9抑制剂在降低低密度脂蛋白胆固醇的同时,可降低脂蛋白(a)约30%。
- 靶向载脂蛋白(a)的反义疗法在1/2期试验中特异性降低脂蛋白(a)浓度最高达90%,且不影响其他血脂。
- 多个药物研发显示强效降低脂蛋白(a)效应,但主要因安全性原因未进入终点研究。
局限性
- 反义疗法的3期结局研究结果尚未公布,需耐心等待。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the mid-1990s, the days of lipoprotein(a) [Lp(a)] were numbered and many people would not have placed a bet on this lipid particle making it to the next century. However, genetic studies brought Lp(a) back to the front-stage after a Mendelian randomization approach used for the first time provided strong support for a causal role of high Lp(a) concentrations in cardiovascular disease and later also for aortic valve stenosis. This encouraged the use of therapeutic interventions to lower Lp(a) as well numerous drug developments, although these approaches mainly targeted LDL cholesterol, while the Lp(a)-lowering effect was only a 'side-effect'. Several drug developments did show a potent Lp(a)-lowering effect but did not make it to endpoint studies, mainly for safety reasons. Currently, three therapeutic approaches are either already in place or look highly promising: (i) lipid apheresis (specific or unspecific for Lp(a)) markedly decreases Lp(a) concentrations as well as cardiovascular endpoints; (ii) PCSK9 inhibitors which, besides lowering LDL cholesterol also decrease Lp(a) by roughly 30%; and (iii) antisense therapy targeting apolipoprotein(a) which has shown to specifically lower Lp(a) concentrations by up to 90% in phase 1 and 2 trials without influencing other lipids. Until the results of phase 3 outcome studies are available for antisense therapy, we will have to exercise patience, but with optimism since never before have we had the tools we have now to prove Koch's extrapolated postulate that lowering high Lp(a) concentrations might be protective against cardiovascular disease.
引用
- Gencer B, Kronenberg F, Stroes ES, et al. Lipoprotein(a): the revenant. Eur Heart J. 2017. PMID: 28329241. doi:10.1093/eurheartj/ehx033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。